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Abstract
This study aimed to determine how hospital level influenced long-term survival for patients with advanced ovarian
cancer. The study population was registered in a prospective population-based registry. All 198 women in Norway
with ovarian cancer International Federation of Gynecology andObstetrics (FIGO) stage IIICwith primary diagnosis
during 2002 were included. Patients operated on at teaching hospitals (THs) achieved better 8-year survival than
did patients operated on at nonteaching hospitals (NTHs).
Background: The aim of this study was to find out the long-term survival of patients with primary International Federation
of Gynecology and Obstetrics (FIGO) stage IIIC epithelial ovarian cancer (EOC IIIC) in a population-based patient cohort
treated in Norway in 2002. Patients and Methods: All 198 women with a diagnosis of EOC IIIC who underwent surgery
were included. The data were derived from notifications to the Norwegian Cancer Registry and medical, surgical, and
histopathologic records. The hospitals were grouped into teaching hospitals (THs) and nonteaching hospitals (NTHs). The
follow-up period was from 0 to 106 months. Results: The long-term survival at 8 years was 15% for women operated on
at THs and 10% for women operated on at NTHs (P .05). The median survival was 35.6 months at THs and 23.4 months
at NTHs (P .05). After simultaneous adjustment for 4 prognostic factors (age, histologic type, grade of differentiation, and
residual disease), the risk of death within 8 years at NTHs was unchanged, with a hazard ratio of 1.38 (95% confidence
interval [CI], 1.00-1.89), compared with THs. Conclusion: Patients operated on for EOC IIIC at THs achieved better
long-term survival than did patients operated on at NTHs. Centralization of EOC IIIC surgery should be introduced in all
countries to improve outcomes for this patient group.
Clinical Ovarian & Other Gynecologic Cancer, Vol. 5, No. 2, 60-6 © 2014 Elsevier Inc. All rights reserved.
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bIntroduction
Epithelial ovarian cancer (EOC) is the female cancer with the
highest mortality rate in the Western world.1 The 5-year relative
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linical Ovarian & Other Gynecologic Cancer December 2012survival rate for patients with EOC in Norway has improved over
time but is still only 44.1% for all stages.2
Four decades ago, Griffiths reported that reducing the residual
tumor to 1.6 cm improved survival,3 and since then the standard
reatment of patients with advanced EOC has been primary cytore-
uction followed by chemotherapy. This finding has been confirmed
y other authors.4-6
In 2007, Paulsen et al showed improved short-term survival in
patients with stage IIIC ovarian, tubal, and peritoneal cancer (EOC
IIIC) when primary surgery was performed at 1 of the 4 teaching
hospitals (THs) in a prospective population-based study in Norway.7
They concluded that patients with EOC IIIC benefited most from
centralized surgery, which has been confirmed by other authors.4-6
The skill of operating physicians who achieved maximal cytoreduc-
tion and optimal chemotherapy were significant factors influencing
survival.7-10
2212-9553/$ - see frontmatter © 2014 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2012.12.002
Table 1 Characteristics of 198 Women With Primary Stage IIIC Ovarian, Tubal, and Peritoneal Cancer Operated on at Different
Hospitals Levels
Characteristics Survival Rate at8 y (%) P Value
THs (%)
n  108
NTHs (%)
n  90 P Value
Age (y)
 65 16  .001 60 (56) 43 (48) NS
 65 10 48 (44) 47 (52)
Emergency Referral
Yes 0  .001 10 (9) 8 (9) NS
No 14 97 (91) 82 (91)
Referral Department
Gynecologic 17  .001 61 (57) 49 (56) NS
Surgical 5 30 (28) 27 (31)
Medical 7 17 (16) 12 (14)
Density of Women per Municipality
 999 8 NS 8 (7) 4 (5) NS
1000-9999 12 52 (48) 53 (60)
10,000-19,999 19 30 (28) 27 (31)
 20,000 9 17 (16) 21 (24)
Performance Status (World Health Organization)
0, normal 20  .001 48 (44) 34 (38) .05
1-2, low 10 53 (49) 40 (44)
3-4, very low 0 2 (2) 14 (16)
Not known 0 5 (5) 2 (2)
Serious Comorbidity (Charlson)
Score 0 14 NS 48 (44) 31 (34) NS
Score 1 14 46 (43) 44 (49)
Score 2 5 10 (9) 11 (12)
Score 3 0 4 (4) 4 (4)
Score 4-5 — 0 0
CA125 Level
 36 33 NS 2 (2) 1 (1) NS
36-150 29 8 (7) 9 (10)
 150 9 83 (77) 59 (66)
Not known 17 15 (14) 21 (23)
Histologic Type
Serous 11 NS 82 (76) 68 (76) NS
Nonserous 19 26 (24) 22 (24)
Differentiation
Well 0 NS 5 (5) 4 (4)  .05
Moderate 5 12 (11) 27 (30)
Poor 16 81 (75) 54 (60)
Not known 7 10 (9) 5 (6)
Ascites
Absent 17 NS 25 (23) 12 (13)  .05
Present 11 82 (76) 72 (80)Not known 17 1 (1) 6 (7)
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62 CThe present study is a follow-up of the prospective population-
based patient cohort with primary EOC IIIC treated in 2002.7 The
aim of the present investigation was to determine how the type of
hospital influenced the long-time survival for these patients. Hospital
level and surgical skill were indicators of the effect centralization had
on the patient’s outcome.
Patients and Methods
Patient Characteristics
All 198 patients in Norway with EOC IIIC diagnosed between
January 1 and December 31, 2002 who underwent operations were
included in this study. Detailed patient characteristics are described
in previous articles.7,11,12 In total, 478 patients with EOC were di-
agnosed in Norway during 2002: 130 stage I and stage II, 308 stage
Table 1 Continued
Characteristics Survival Rate8 y (%)
Preoperative Tumor Diameter
 15 cm 14
 15 cm 10
Surgery
Optimala 18
Not optimal 3
Not known 0
Residual site
No visible disease 31
Pelvis only 0
Upper abdomen onlyb 14
Upper and lower abdomenc 5
Postoperative Mortality
 30 days —
 30 days —
Neoadjuvant Chemotherapy
Yes 4
No 14
Chemotherapy
Platinum-based paclitaxel 17
Platinum-based single agent 3
Other agents —
No chemotherapy 0
 5 courses 2
 6 courses 17
Time Interval Surgery-Chemotherapy (n  178)
 30 days 13
 30 days 15
Abbreviations: CA125 cancer antigen 125; NS not significant; NTHs nonteaching hosp
a Hysterectomy, bilateral salpingo-oophorectomy, omentectomy, tumor extirpation.
b Diaphragm, liver surface, spleen.
c Upper abdomen, abdominal peritoneum, pelvis.III, 72 stage IV, and 42 unstaged patients. Many patients in the latter o
linical Ovarian & Other Gynecologic Cancer December 2012group did not undergo operation.11 The following patient charac-
eristics are given in Table 1: age ( 65 years or  65 years), emer-
ency referral (patients admitted to the hospital within 24 hours after
heir first referrals from general practitioners or gynecologists: yes,
o), referral department at first consultation (gynecologic, surgical,
r medical).
To investigate the effect of place of residence on referral practice,
he municipalities were divided into 4 categories according to the
umber of women  20 years of age living in each ( 999; 1000-
999; 10,000-19,999;  20,000). Serious comorbidity (Charlson
core 0-5), cancer antigen 125 (CA125) in kilo units per liter, ascites
absent,  100 mL; present, 100 mL), the maximal preoperative
umor diameter (measured by the operating physician at primary
P Value THs (%)n  108
NTHs (%)
n  90 P Value
NS 71 (66) 58 (64) NS
37 (34) 32 (36)
 .001 80 (75) 48 (53)  .05
27 (25) 40 (44)
1 2
 .001 32 (30) 16 (18)  .05
6 (6) 12 (13)
23 (21) 13 (14)
47 (44) 49 (54)
0 9 (10)  .001
108 (100) 81 (90)
NS 24 (22) 0 —
84 (78) 90 (100)
 .001 88 (82) 51 (56)  .01
16 (15) 13 (14)
1 (1) 1 (1)
3 (3) 25 (28)
 .001 91 (84) 51 (57)  .01
17 (16) 39 (43)
NS 47 (56) 21 (23)  .001
37 (44) 69 (77)
s teaching hospitals.at
itals; THperation or on scanning with computed tomography or magnetic
Torbjørn Paulsen et alresonance imaging before treatment ( 15 cm;  15 cm), surgery
(optimal surgery defined as hysterectomy, bilateral salpingo-oopho-
rectomy, omentectomy, and tumor resection; nonoptimal surgery
defined as less than optimal surgery), site of residual disease (pelvis
only; upper abdomen only [diaphragm, liver surface, spleen]; upper
and lower abdomen), postoperative mortality ( 30 days;  30
days), neoadjuvant chemotherapy (yes or no). Three courses of neo-
adjuvant chemotherapy (paclitaxel platinum-based therapy) were
given to 23 patients before operation.
Statistical Analysis
All analyses were performed with SPSS Statistics, version 17.0
(SPSS Inc, Chicago, IL). The Pearson 2 test was used to compare
the frequencies of the prognostic factors, residual disease, and che-
motherapy according to hospital type (Table 1).
Kaplan-Meier plots were used to show the survival patterns of the
patients according to hospital type, residual disease, and SCI. The
log-rank test was used to test differences in survival among the vari-
ous groups in the Kaplan-Meier plots (Figures 1-3).
The Cox proportional hazards model was used to estimate the
effect of the prognostic factors on survival. We also adjusted for the
amount of residual disease separately and with a combination of 3
other prognostic factors: age, histologic type, and grade of differen-
tiation in the Cox model (Table 2). Spearman nonparametric corre-
lation coefficients were estimated for the prognostic factors to deter-
Figure 1 Kaplan-Meier Survival Curves for Advanced Ovarian/
Peritoneal/Tubal Cancer by Level of Hospital at
Which Surgery was Performed. Log-Rank P < .05.
Number of Patients Treated at a Teaching Hospital
(TH) was 108 (8-Year Survival, 15%; 93 Patients
Were Dead at End of Follow-Up). Number of
Patients Treated at a Nonteaching Hospital (NTH)
was 90 (8-Year Survival, 10%; 82 Patients Were
Dead at End of Follow-Up).   Censored
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TH 108 (93)
NTH 90 (82)mine the degree of correlation (not shown).Survival Analysis
Survival is calculated for patients not receiving neoadjuvant
chemotherapy (n  174) and surgery-chemotherapy interval
(SCI) (days from primary surgery until first cycle of chemother-
apy,  30 days or  30 days). Survival time was calculated from
date of diagnosis until date of death or November 1, 2010, which-
ever occurred first. The date of diagnosis was defined as date of
operation or date of cytologic/histologic verification. The mean
and median follow-up time was 38.5 and 29.5 months (range,
0-106 months).
Health Care Organization
Norway is divided into 4 health regions with a TH in each region.
The patients were operated on at 34 nonteaching hospitals (NTHs)
and 4 THs with a gynecologic oncology unit and a medical school
attached.
The specialized gynecologist was responsible for the primary che-
motherapy treatment at the TH, whereas a general gynecologist or
medical oncologist was responsible at the other hospitals. Most of the
patients were referred to the TH for initiation of chemotherapy after
primary surgery.
Norway has a national health care system covering all inhabitants.
Private insurance coverage does not contribute to the ability to have
optimal cancer treatment in Norway. The travel expenses to the
Figure 2 Kaplan-Meier Survival Curves for Advanced Ovarian/
Peritoneal/Tubal Cancer by Residual Disease. Log-
Rank P < .001. Number of Patients Who Had No
Residual Disease After Treatment was 33, (8-Year
Survival, 30%; 25 Patients Were Dead at End of
Follow-up). Number of Patients Who Had Visible
Residual Disease After Treatment was 165 (8-Year
Survival, 7%; 150 Patients Were Dead at End of
Follow-Up).   Censored
Survival in Years
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Residual disease 165 (150)
No residual disease 33 (25)hospital are covered by the national health care insurance.
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64 CResults
Variation in Patient Characteristics
There were no differences in age, emergency referral, serious co-
morbidities, CA125 levels, histologic types, and preoperative tumor
diameter between the 2 groups (Table 1). There were significantly
more patients in the TH group who had tumors with poor differen-
tiation, received neoadjuvant and standard chemotherapy, and had a
 30-day SCI. In the NTH group, there were significantly more
patients with lower World Health Organization performance status,
ascites, and higher 30-day postoperative mortality. A shorter sur-
vival time was found for older women than for younger women
(Table 1). More patients had optimal surgery at THs compared with
NTHs, 75% vs. 53% (P  .05), resulting in more patients with no
visible disease: 31% in the TH group compared with 18% in the
NTH group (P  .05). Among patients operated on at THs, 21%
had only upper abdominal residual disease compared with 14%
among patients operated on at NTHs. The diaphragm, abdominal
peritoneum, and pelvis were the most frequent sites of residual tumor
in patients operated on at both THs and NTHs.
Survival Analysis
The median survival was 35.6 months at THs and 23.4 months at
NTHs. After 8 years, the survival of patients operated on at THs was
15% compared with 10% of those operated on at NTHs (P  .05)
Figure 1). In patients whose tumors were optimally debulked to no
isible tumor during primary surgery, the survival rate was 31% after
years, whereas in patients with visible residual disease, the survival
ate was 7% (P  .001) (Figure 2).
Patients who were operated on after an emergency admission were
Figure 3 Kaplan-Meier Survival Curves for Advanced Ovarian/
Peritoneal/Tubal Cancer by Surgery-Chemotherapy
Interval (SCI). Log-rank Test P  .3. Number of
Patients Treated With an SCI < 30 Days was 68
(8-Year Survival, 8%; 61 Patients Were Dead at End
of Follow-Up). Number of Patients Treated With an
SCI > 30 Days was 106 (8-Year Survival, 15%; 91
Patients Were Dead at End of Follow-Up).  
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SCI > 30 days 106 (91)
SCI ≤ 30 days 68 (61)qually distributed among THs and NTHs (not significant [NS]). e
linical Ovarian & Other Gynecologic Cancer December 2012All patients were dead after 5 years and 10 months when operated on
in connection with an emergency admission at primary treatment.
Serious comorbidity according to Charlson score was equally dis-
tributed between THs and NTHs. The survival rates at 8 years were
14% at scores 0 and 1, only 5% at score 2, and 0% at score 3; however
10% more patients with score 0 were operated on at THs and 6%
more patients with score 1 were operated on at NTHs. All patients
with score 3 were dead after 4 years and 4 months (not shown). None
of the patients operated on at THs died within 30 days after the
operation, whereas 10% of the patients operated on at NTHs died
within this time (P  .001).
No patients had neoadjuvant chemotherapy in the NTH group;
4% of patients were alive after 8 years when treated with neoadjuvant
chemotherapy, whereas among patients who were operated on ac-
cording to a planned primary operation, 14% were alive (NS).
Among patients who underwent primary surgery and no neoadjuvant
chemotherapy treatment (n 174), there was an improved survival rate
of 24% after 2 years when they had the first course of chemotherapy
within 30 days after surgery. After 6 years of observation, the survival
curves converge, with no benefit of having the first course of chemother-
apy within 30 days after primary surgery (NS) (Figure 3).
If we eliminate patients who died within 30 days after surgery at
NTHs (n 9) and patients who did not receive chemotherapy (n
8), the 5- and 8-year survival at THs is 43% and 14% compared
ith 12% and 0% at NTHs (NS).
Cox Regression Analysis
The crude mortality rate after 8 years was lower for patients oper-
ated on at THs than for patients operated on at NTHs; the hazard
ratio was 1.36 (95% confidence interval [CI], 1.01-1.82) (Table 2).
omen operated on at NTHs still had an increased risk for death,
ith a hazard ratio of 1.38 (95% CI, 1.00-1.89) after simultaneous
djustment for the 4 most important prognostic factors (age, histo-
ogic type, grade of differentiation, and residual disease).
Discussion
In this prospective population-based cohort of patients with EOC
IIIC, there is still a significant difference in survival between patients
operated on at THs and those operated on at NTHs after 8 years.
The hazard ratio for patients with EOC IIIC operated on at NTHs
by a gynecologist was 1.36 (CI, 1.01-1.82) higher in the unadjusted
group, 1.23 higher (CI, 0.91-1.66) when adjusted for residual dis-
ease, and 1.38 higher in the groups adjusted for the 4 prognostic
factors. The emergency referral frequency was equally distributed
between the hospital levels and cannot explain difference in survival.
The observation is partly explained by better surgical skills and che-
motherapy at THs. Patient selection and different tumor biological
characteristics may also contribute to the difference in survival.
Other authors have come to the same conclusions based on retro-
spective study designs.8,13
Other investigators have shown that more extensive surgery is
carried out at THs.13,14 In the current study, the importance of this
rognostic factor was confirmed by the results of the multivariate
nalysis and the survival analysis according to the extent of residual
umor in both TH and NTH groups.
Probably the most important prognostic factor was when the op-
rating physician achieved no residual disease, which is in accordance
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Torbjørn Paulsen et alwith other investigators.8,15-19 Aletti et al demonstrated that residual
isease was the only independent predictor for survival.19 According
to Chi et al, this radical surgery requires the expertise of a gynecologic
oncologist but may also necessitate the assistance of general surgeons,
surgical oncologists, or liver surgeons, particularly when there is ex-
tensive upper abdominal disease.20 In both THs and NTHs, there is
potential for improvement in surgery. The number of patients whose
disease is optimally debulked (0 cm residual disease) must be in-
creased at all THs in Norway. One way to achieve this goal is to
incorporate extensive upper abdominal procedures into the operative
strategy. This may increase the rate of primary optimal cytoreduction
without increasing postoperative morbidity and mortality.20 Two
thirds of patients operated on at both THs and NTHs had upper
abdominal residual disease.
The preoperative tumor load is the same at THs and NTHs,
which confirms that at both hospital levels patients have the same
potential for their tumors being optimally debulked. Operating phy-
sicians at THs succeed in optimally debulking to 0 cm in 30% of
cases compared with 18% of cases among operating physicians at
NTHs. This may reflect that the operating physicians at THs are
more skilled or put more effort into achieving optimal cytoreduction.
In the present study, the postoperative mortality within 30 days
was 4.5%. This was in accordance with 2.5% in the study by Vergote
et al.21 No patients died before 30 days after surgery at THs com-
ared with 9 in the NTH group, which gives the patients operated on
t THs improved short-term survival. This advantage in survival was
aintained for the next 8 years. The hazard ratio did not change
ignificantly if these patients were excluded from the analyses. We
id not observe a significant correlation between comorbidity and
eath within 30 days either (NS).
In a previous article, a comorbidity score with 2 levels was used for
djustments in the Cox regression analysis7; however this score was
ot evaluated against mortality. We therefore calculated a comorbid-
ty score based on a scale (0-5) that was evaluated against the mor-
ality in a breast cancer population (Charlson score).22 This score is
also evaluated for other cancers including ovarian cancer.23-25 In the
resent study, the patients had increased mortality with increased
harlson scores (except score 1). The score was equally distributed
etween the hospital levels. The Charlson score did not change the
azard ratios after adjusting for it in the Cox regression analysis.
The Charlson score was published in 1987.22 However there has
een progress in the treatment for some of the diseases that form the
asis for this score since then. Some of the diseases may have a more
avorable prognosis today (heart disease, acquired immunodeficiency
yndrome). Hence the score may overestimate the death rate for these
Table 2 Hazard Ratios (95% CI) for Patients With Stage IIIC Ov
Unadjusted CI Adjusted Residual Dise
THs 1 1
NTHs 1.36 1.01-1.82 1.23
Abbreviations: CI confidence interval; NTHs nonteaching hospitals; THs teaching hospi
a Cox regression analysis.
b Age, histologic type, grade of differentiation, residual disease.iseases and invalidate our results. However the comorbidity wasublished in our previous article7 and the Charlson score had a high
degree of correlation.
There is a tendency for younger patients to undergo operation at
THs rather than NTHs, which may explain the better survival
among patients treated at THs. In our study, the patients are older
than in the population-based Australian study from Laurvick et al, in
which the mean age was 8 years younger than in the present study.26
Obviously there are some selection mechanisms for patients
treated at the 2 hospital levels. The patients operated on at NTHs
were older and had lower performance status. Some of these patients
might have benefited from neoadjuvant chemotherapy. However pa-
tients referred to NTHs were not admitted more often to medical or
surgical departments nor were they from rural areas, so these condi-
tions could not explain the selection to NTHs.
In the present study, patients who were not expected to achieve
optimal surgery upfront were more likely to have neoadjuvant che-
motherapy. In a large randomized multicenter study, Vergote et al
showed that patients who received neoadjuvant chemotherapy had
the same survival rates as patients with surgery upfront.21 Preopera-
ive tumor burden was smaller in the present study compared with
hat in the study from Vergote et al. This results from underestimat-
ng the real tumor size. Préfontaine et al found that surgeons under-
stimated rather than overestimated tumor diameters.27 Patients
ho received chemotherapy within 30 days after primary surgery had
mproved survival during the first 5 years. During the last 3 years of
bservation, no survival benefits were seen from chemotherapy given
ithin 30 days after surgery.
Our findings show a benefit of long-term survival for women with
nternational Federation of Gynecology and Obstetrics (FIGO)
tage IIIC ovarian cancer when they are operated on at THs and
iven chemotherapy within 30 days after primary surgery. Central-
zation of surgery and improvement in chemotherapy distribution
ight therefore improve the outcome for patients with ovarian
ancer.
Ethics
The Norwegian Cancer Registry has approval from the Cancer
Registry Regulations to carry out surveillance using the data they
collect on all cancer patients in Norway.28
Clinical Practice Points
● Many authors have demonstrated that reducing the tumor burden
to a minimum improves survival for patients with advanced ovar-
Cancer Operated on at Different Hospital Levelsa
CI Adjusted 4 Prognostic Factorsb CI
1
0.91-1.66 1.38 1.00-1.89arian
ase
tals.ian cancer.
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66 C● Treatment in centralized hospitals (THs) compared with local
hospitals (NTHs) resulted in better long-term survival for patients
with advanced ovarian cancer.
● Patients with advanced ovarian cancer should be treated at central-
ized institutions with skilled oncologic/gynecologic surgeons and
physicians trained in administrating chemotherapy.
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